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Objective: The aim was to formulate practice guidelines for endocrine evaluation and treatment
of pituitary incidentalomas.
Consensus Process: Consensus was guided by systematic reviews of evidence and discussions
through a series of conference calls and e-mails and one in-person meeting.
Conclusions: We recommend that patients with a pituitary incidentaloma undergo a complete
history and physical examination, laboratory evaluations screening for hormone hypersecretion
and for hypopituitarism, and a visual field examination if the lesion abuts the optic nerves or
chiasm.Werecommendthatpatientswith incidentalomasnotmeetingcriteria for surgical removal
be followedwith clinical assessments, neuroimaging (magnetic resonance imaging at 6months for
macroincidentalomas, 1 yr for a microincidentaloma, and thereafter progressively less frequently
if unchanged in size), visual field examinations for incidentalomas that abut or compress the optic
nerve and chiasm (6months and yearly), andendocrine testing formacroincidentalomas (6months
and yearly) after the initial evaluations. We recommend that patients with a pituitary inci-
dentaloma be referred for surgery if they have a visual field deficit; signs of compression by the
tumor leading to other visual abnormalities, such as ophthalmoplegia, or neurological com-
promise due to compression by the lesion; a lesion abutting the optic nerves or chiasm; pituitary
apoplexy with visual disturbance; or if the incidentaloma is a hypersecreting tumor other than
a prolactinoma. (J Clin Endocrinol Metab 96: 894–904, 2011)
Summary of Recommendations
1.0 Initial evaluation of a patient with a pituitary
incidentaloma
1.1 We recommend that patients presenting with a pi-
tuitary incidentaloma undergo a complete history and
physical examination that includes evaluations for evi-
dence of hypopituitarism and a hormone hypersecretion
syndrome. Patients with evidence of either of these con-
ditions should undergo an appropriately directed bio-
chemical evaluation:
1.1.1 We recommend that all patients with a pituitary
incidentaloma, including those without symptoms, un-
dergo clinical and laboratory evaluations for hormone hy-
persecretion (1QQQE).
1.1.2 We recommend that patients with a pituitary inci-
dentaloma with or without symptoms also undergo clinical
and laboratory evaluations for hypopituitarism (1QQQE).
1.1.3 We recommend that all patients presenting with
a pituitary incidentaloma abutting the optic nerves or chi-
asm onmagnetic resonance imaging (MRI) undergo a for-
mal visual field (VF) examination (1QQQQ).
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Abbreviations:CT,Computed tomography;GHD,GHdeficiency;MRI,magnetic resonance
imaging; VF, visual field.
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1.1.4We recommend that all patients have aMRI scan,
if possible, to evaluate the pituitary incidentaloma [if the
incidentaloma was initially only diagnosed by computed
tomography (CT) scan] to better delineate the nature and
extent of the incidentaloma (1QQQQ).
2.0 Follow-up testing of the pituitary
incidentaloma
2.1 Patients with incidentalomas who do not meet cri-
teria for surgical removal of the tumor should receive non-
surgical follow-up (2QQEE) with clinical assessments
and the following tests:
2.1.1 MRI scan of the pituitary 6 months after the ini-
tial scan if the incidentaloma is amacroincidentaloma and
1 yr after the initial scan if it is a microincidentaloma
(1QQEE). In patients whose incidentaloma does not
change in size,we suggest repeating theMRI every year for
macroincidentalomas and every 1–2 yr in microinciden-
talomas for the following 3 yr, and gradually less fre-
quently thereafter (2QQEE).
2.1.2VFtesting inpatientswithapituitary incidentaloma
that enlarges to abut or compress the optic nerves or chiasm
on a follow-up imaging study (1QQQQ). We suggest that
clinicians do not need to test VF in patients whose inciden-
talomas are not close to the chiasm and who have no new
symptoms and are being followed closely by MRI
(2QEEE).
2.1.3 Clinical and biochemical evaluations for hypop-
ituitarism 6 months after the initial testing and yearly
thereafter in patients with a pituitary macroincidenta-
loma, although typically hypopituitarism develops with
the finding of an increase in size of the incidentaloma
(1QQEE). We suggest that clinicians do not need to test
for hypopituitarism in patients with pituitary microinci-
dentalomas whose clinical picture, history, and MRI do
not change over time (2QQEE).
2.2 Patients who develop any signs or symptoms po-
tentially related to the incidentaloma or who show an in-
crease in size of the incidentalomaonMRI shouldundergo
more frequent or detailed evaluations as indicated clini-
cally (1QQEE).
3.0 Indications for surgical therapy of the pituitary
incidentaloma
3.1 We recommend that patients with a pituitary inci-
dentaloma be referred for surgery if they have the follow-
ing (1QQQQ):
• A VF deficit due to the lesion.
• Other visual abnormalities, such as ophthalmoplegia
or neurological compromise due to compression by
the lesion.
• Lesion abutting or compressing the optic nerves or
chiasm on MRI.
• Pituitary apoplexy with visual disturbance.
• Hypersecreting tumors other than prolactinomas as
recommended by other guidelines of The Endocrine
Society and The Pituitary Society.
3.2 We suggest that surgery be considered for patients
with a pituitary incidentaloma if they have the following
(2QQEE):
• Clinically significant growth of the pituitary
incidentaloma.
• Loss of endocrinological function.
• A lesion close to the optic chiasm and a plan to be-
come pregnant.
• Unremitting headache.
Method of Development of Evidence-
Based Clinical Practice Guidelines
The Clinical Guidelines Subcommittee of The Endocrine
Society deemed the subject of pituitary incidentalomas a
priority area in need of practice guidelines and appointed
a Task Force to formulate evidence-based recommenda-
tions. Consensus was guided by systematic reviews of ev-
idence and discussions through a series of conference calls
and e-mails and one in-person meeting. An initial draft
guidelinewas prepared by the Task Force, with the help of
a medical writer, and reviewed and commented on by
members of The Endocrine Society and the European So-
ciety of Endocrinology. A second draft was reviewed and
approvedbyTheEndocrine SocietyCouncil. At each stage
of review, the Task Force received written comments and
incorporated substantive changes. The evidence was de-
veloped using the Grading of Recommendations, Assess-
ment, Development, and Evaluation (GRADE) system to
describe the strength of recommendations and the quality
of evidence, which was low or very low. The GRADE
group is an international group with expertise in devel-
opment and implementation of evidence-based guidelines
(1). A detailed description of the grading scheme has been
published elsewhere (2). The Task Force used the best
available research evidence identified and one commis-
sioned systematic review to develop some of the recom-
mendations (3). The Task Force also used consistent lan-
guage and graphical descriptions of both the strength of a
recommendation and the quality of evidence. In terms of
the strength of the recommendation, strong recommen-
dations use the phrase “we recommend” and the number
1, and weak recommendations use the phrase “we sug-
gest” and the number 2. Cross-filled circles indicate the
quality of the evidence, such thatQEEE denotes very low
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quality evidence; QQEE, low quality; QQQE, moderate
quality; and QQQQ, high quality. The final category may
include circumstances in which there is a consistent ob-
servationof uniformly poor serious outcomes thatwill not
reverse spontaneously, but when treated, often through
surgical means, may dramatically improve or be cured.
The Task Force has confidence that persons who receive
care according to the strong recommendationswill derive,
on average, more good than harm. Weak recommenda-
tions require more careful consideration of the person’s
circumstances, values, and preferences to determine the
best course of action. Linked to each recommendation is
a description of the evidence and the values that panelists
considered in making the recommendation; in some in-
stances, there are remarks, a section in which panelists
offer technical suggestions for testing conditions, dosing,
and monitoring. These technical comments reflect the
best available evidence applied to a typical person being
treated. Often this evidence comes from the unsystem-
atic observations of the panelists and their values and
preferences; therefore, these remarks should be consid-
ered suggestions.
Definition, etiology, and epidemiology of pituitary
incidentalomas
Definition of pituitary incidentaloma
A pituitary incidentaloma is a previously unsuspected
pituitary lesion that is discovered on an imaging study
performed for an unrelated reason. By definition, the im-
aging study is not done for a symptom specifically related
to the lesion, such as visual loss, or a clinicalmanifestation
of hypopituitarism or hormone excess, but rather for the
evaluation of symptoms such as headache, or other head
or neck neurological or central nervous system complaints
or head trauma (4–9). Studies reviewed for these guide-
lines vary, however, in their definition of a “pituitary in-
cidentaloma.” For example, some studies exclude cystic
lesions and include only those that fulfill radiographic
criteria for a pituitary adenoma (4, 5), whereas others
include all lesions (6–9). The guidelines presented here
are relevant to all pituitary incidentalomas, those that
have the appearance typical of a pituitary adenoma as
well as cystic lesions. By convention, microincidenta-
lomas are less than 1 cm and macroincidentalomas are
at least 1 cm in size.
Etiology of pituitary incidentalomas
Because incidentalomas infrequently come to surgery,
the true pathological diagnoses of most are unknown. In
a series of sellar masses that required surgery, 91% were
pituitary adenomas and about 9%were nonpituitary in
origin, of which most were craniopharyngiomas and
Rathke’s cleft cysts (10). It is unknown whether the
etiologies of incidentalomas are similar to this surgical
cohort, but in one series of 29 incidentalomas that did
come to surgery, 23 were found to be pituitary adeno-
mas, four were Rathke’s cleft cysts, and two were cra-
niopharyngiomas (6, 7, 9). Immunohistochemical anal-
ysis of 20 of these adenomas was reported as negative in
50%, plurihormonal in 20%, gonadotroph positive in
15%, andGHpositive in 10% (6, 7, 9). In another series
of 139 mass lesions without overt symptoms, 73 had a
cystic appearance on imaging study (5). Cystic lesions
are most likely to be Rathke’s cleft cysts, which often
present incidentally, or craniopharyngiomas (11, 12).
Of the non-cystic-appearing incidentalomas, nearly all
are likely to be pituitary adenomas, and most clinically
nonfunctioning pituitary adenomas are of gonadotrope
origin as determined by immunocytochemical studies
(13–15). However, the differential diagnosis of sellar
incidentalomas is broad and should include other pos-
sibilities (10).
Epidemiology of pituitary incidentalomas
The prevalence of pituitary incidentalomas has been
estimated from data on pituitary adenomas found at au-
topsy and from imaging in patients who underwent a CT
or MRI of the head for reasons other than pituitary dis-
ease. Because most pituitary incidentalomas are adeno-
mas, autopsy data on adenomasmay provide information
relevant to incidentaloma detected during life. In com-
bined autopsy data, the average frequency of a pituitary
adenoma was 10.6% (16). The tumors were distributed
equally across genders and the adult age range, and nearly
all of these incidentalomas were microadenomas (16). In
adults who underwent cranial imaging studies for reasons
other than pituitary disease, microincidentalomas were
seen onCT in 4–20% (17–19) or onMRI in 10–38% (20)
of patients. Macroincidentalomas were found in 0.2% of
patients who underwent CT scans for central nervous sys-
tem symptoms (21) and byMRI in 0.16%of a population
study cohort (22). In pooled data from 10 series of pitu-
itary incidentalomas, 160 of 353 (45%) were macroinci-
dentalomas (4–9, 23–26), a larger percentage than has
been found on autopsy studies and the other screening
studies. This suggests that these patients may in fact have
had some symptom that was not readily apparent or re-
ported but that led to the imaging study or that microin-
cidentalomas were not referred to these centers for
evaluation.
Data are not available on pituitary incidentalomas in
the pediatric population; these guidelines are limited to
adults.
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1.0 Initial evaluation of a patient with a pituitary
incidentaloma
Recommendations
1.1 We recommend that patients presenting with a pi-
tuitary incidentaloma undergo a complete history and
physical examination that includes evaluations for evi-
dence of hypopituitarism and a hormone hypersecretion
syndrome. Patients with evidence of either of these con-
ditions should undergo an appropriately directed bio-
chemical evaluation.
1.1.1 We recommend that all patients with a pituitary
incidentaloma, including those without symptoms, un-
dergo clinical and laboratory evaluations for hormone hy-
persecretion (1QQQE).
1.1–1.1.1 Evidence
The goals of the endocrine evaluation of pituitary in-
cidentalomas are to identify hormone hypersecretion and
hypopituitarism. The recommendations for evaluation of
pituitary function considered the likelihood of an abnor-
mality in a given patient. However, valid estimates of the
pretest probability of an abnormal test of pituitary func-
tion could not be definitively determined because litera-
ture on this topic is sparse. Therefore, recommendations
for the evaluation relied heavily on clinical experience.
Data on the prevalence of hormone hypersecretion in
patients with an incidentaloma are available from small
observational studies (most retrospective) and estimated
from autopsy data. Screening for hypersecretion is impor-
tant toperformbecause theprevalenceof clinically evident
pituitary adenomas has recently been appreciated to be as
high as 1/1000 in a Belgian population (27), and 0.776/
1000 (of which 0.542/1000 were hormone secreting) in a
region of theUnitedKingdom (28), or as lowas 0.04/1000
in Finland (29). The incidence of incidentally discovered
pituitary adenomas was recently reported as 0.016/1000
in a retrospective review from Finland (29).
The evaluation for hypersecretion should include an
assessment for prolactin, GH, and ACTH hypersecretion.
Evidence is strongest for the need tomeasure a serum pro-
lactin level in all patients presenting with an incidenta-
loma. Ideally, for patients with large macroincidentalo-
mas, the laboratory should measure prolactin levels in
diluted serum to ensure that levels are not falsely lowered
by a hook effect in the assay. Hyperprolactinemia was
found in five of 42 patients with microincidentalomas at
initial evaluation (4), but in other studies none of 22 de-
veloped a prolactin elevation on prospective follow-up (8,
9). In other studies, prolactinomas were detected in seven
of46patientswith incidentalomas (microandmacro com-
bined) (7). In macroincidentalomas, prolactin levels were
elevated in two of 16 (9). In a large autopsy study, 39.5%
of the adenomas detected (most microadenomas) were
found to stainpositive for prolactin (30).These datamight
suggest that prolactinomas are very common among pi-
tuitary incidentalomas, which is contrary to the literature.
Autopsy data should cautiously be considered represen-
tative of incidentalomas presenting in life because the au-
topsy studies lack clinical data, and prolactin stainingmay
not have been associated with clinically relevant circulat-
inghyperprolactinemia. Patientswithhyperprolactinemia
could receive a trial of dopamine agonist therapy so long
as it is recognized that mild/moderate elevations may be
due to stalk compression from a lesion other than a pro-
lactinoma. In these patients, tumor shrinkage is unlikely,
and growth of the incidentaloma is still possible, so con-
tinued follow-up with repeat imaging is warranted. The
treatment of hyperprolactinemia has been recently re-
viewed (31).
Although silent somatotroph-secreting tumors are rare,
evaluation for the possibility is recommended. In a pro-
spective study, one of 11 macroincidentalomas were
found tohave an elevated IGF-I consistentwith subclinical
GH excess (8), and in another study, two of 13 inciden-
talomas that were surgically removed were positive on
immunohistochemistry for GH (7). One series of 3048
autopsies reported 334 pituitary adenomas, of which
1.8% stained positive for GH (30). Because the initial
treatment for a GH-secreting tumor is surgery and GH-
secretingmicroadenomascanbecured surgically inalmost
all cases, screening for a GH-secreting tumor by measure-
ment of an IGF-I level is warranted. If this is elevated,
further evaluation for GH excess is suggested.
Screening for glucocorticoid excess due to a possible
corticotroph tumor may also be considered when this is
suspected clinically. In the series of 3048autopsies, 13.8%
of 334 pituitary adenomas stained positive for ACTH
(30). No systematic screening of incidentalomas for sub-
clinical glucocorticoid excess has been reported (8, 9).
However, patients with adrenal incidentalomas may have
Cushing’s syndrome-associated morbidities such as dia-
betes mellitus, hypertension, obesity, and osteoporosis
(32), so in a patient with a pituitary incidentaloma sub-
clinical Cushing’s disease could also be associated with
thesemorbidities (16). In patients with a clinical suspicion
for glucocorticoid excess, laboratory screening is there-
fore suggested. Detection of subclinical hypercortisolism
should be followed by evaluation for possible Cushing’s
disease. The screening and evaluation of Cushing’s dis-
ease has been reviewed in the “Diagnosis of Cushing’s
Syndrome: an Endocrine Society Clinical Practice
Guideline” (33).
The Task Force does not recommend the routine mea-
surement of plasmaACTH levels in patients with inciden-
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talomas.However, some of the Task Forcemembers often
measure ACTH because a small percentage of inciden-
talomas may be silent corticotroph tumors (34), and
occasionally plasma ACTH levels are elevated in pa-
tients harboring these tumors despite the lack of clinical
manifestations of cortisol excess (34).
In patients whose personal or family history suggests
the possibility of a multiple endocrine neoplasia syn-
drome, additional screening and follow-up as appropriate
to the suspected syndrome should be undertaken.
1.1–1.1.1 Values and preferences
The recommendations for screening for hypersecretion
needed to balance the potential benefits of early detection
with the relatively low likelihood of finding certain ab-
normalities in a given patient and the costs and burden of
potentially unnecessary testing.
Screening for certain hormone hypersecretion syn-
dromes was considered important, even if the patient was
asymptomatic or if the abnormality was unlikely in the
patient population. Screening for hyperprolactinemiawas
considered essential because of the potential for successful
treatment with an oral dopamine agonist. Screening for
GH excess with a serum IGF-I level was recommended
because early detection of a GH-secreting tumor, which
would likely be asymptomatic, could reduce long-term
morbidity and increase the likelihood of surgical cure.
Some consider screening also for glucocorticoid excess in
all patients, but others may limit screening to patients for
whom there is a clinical suspicion, due to the high false-
positive rate and low rate of true-positive testing in the
former group of patients.
1.1–1.1.1 Remarks
The pros and cons of detailed vs. limited screening for
hypersecretion syndromes (other than for prolactinoma)
were debated, and the Task Force was split on this point.
The quality of evidence for or against one particular test-
ing strategy was weak.
Recommendation
1.1.2 We recommend that patients with a pituitary in-
cidentaloma with or without symptoms also undergo
clinical and laboratory evaluations for hypopituitarism
(1QQQE).
1.1.2 Evidence
Evidence to support screening for hypopituitarism in
patients with an incidentaloma also comes from small ob-
servational studies. In combined data in micro- and mac-
roincidentalomas, hypopituitarismwaspresent in sevenof
66 (5) and 19 of 46 patients (7). Deficits of gonadotropins
(not associatedwith hyperprolactinemia)were detected in
up to 30% of patients (4, 7, 8), of the ACTH/cortisol axis
in up to 18% (7, 8), thyroid axis in up to 28% (7, 8), and
GH axis in up to 8% (4).
Different approaches can be taken to the initial evalu-
ation of the patient for hypopituitarism. Some Task Force
members recommend a minimal screening with the mea-
surement of free T4, morning cortisol, and testosterone
levels, whereas others recommend that the initial evalua-
tion shouldalso include themeasurementofTSH,LH,and
FSH and IGF-I. A broad initial approach to this testing is
favoredby some to avoid the repeatedblood sampling that
wouldbeneeded to confirmacentral originof targetorgan
deficiencies should they be detected. Low gonadotropin
levels in postmenopausal women provide evidence of hy-
popituitarism and inmen exclude primary hypogonadism
when testosterone levels are low. Similarly, normal or low
TSH levels help distinguish a pituitary etiology of hypo-
thyroidism when the free T4 is low. Gonadal function can
be assessed in premenopausal women by history and ex-
amination. If baseline testing suggests hypopituitarism,
further stimulation tests of the pituitary-adrenal or GH-
IGF-I axis should be performed.
1.1.2 Values and preferences
The size of the incidentaloma may also be relevant to
the risk of hypopituitarism, so the Task Force debated
whether the size should factor into the decision to screen
or not to screen for hypopituitarism. TheTask Forcemore
strongly favored routine testing for hypopituitarism in
macroincidentalomas and larger microincidentalomas,
for example 6–9 mm, and not necessarily in smaller mi-
croincidentalomas because asymptomatic pituitary hor-
mone deficits can be detected and larger lesions seemmore
likely to be associated with hypopituitarism. Although
there are no specific data on the prevalence of hypopitu-
itarism in larger vs. smaller microincidentalomas, in the
Task Force’s experience some largermicroincidentalomas
may behave more like macroincidentalomas, which leads
some endocrinologists to routinely evaluate larger micro-
incidentalomas for hypopituitarism. Routine screening
for hypopituitarism among smaller microincidentalomas
may not be necessary because the rate of hypopituitarism
among them appears to be very low, although the number
of patients reported is very small (4, 8, 9).However, recent
data do show that hypopituitarism can occur in microad-
enomas (35). The Task Force recognized that there is a
continuum of size of pituitary incidentalomas, so a 1-cm
size cutoff may be arbitrary in evaluating the risk of hy-
popituitarism and other anatomic characteristics of the
incidentaloma need to be considered. The evidence was
downgraded because only observational data from rela-
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tively small studies are available, and some decisions had
to be made based on the clinical experiences of the Task
Force members rather than rigorous studies.
1.1.2 Remarks
Our recommendations include routine screening for
GH deficiency (GHD) with an IGF-I level in all patients,
but theTaskForce recognized that this alone is insufficient
evidence for or against GHD in adults. In patients with a
clinical suspicion ofGHD, in particular if the IGF-I is low,
further testing should be undertaken as recommended in
the “Evaluation and Treatment of Adult Growth Hor-
mone Deficiency: an Endocrine Society Clinical Practice
Guideline” (36). The authors of this guideline also recog-
nized that the approach taken to the testing for and treat-
ment of GHD varies among endocrinologists and that
some would only consider performing the testing if the
clinical setting suggested the potential for a benefit of GH
therapy.
Recommendation
1.1.3 We recommend that all patients presenting with
a pituitary incidentaloma abutting or compressing the op-
tic nerves or chiasm onMRI undergo a
formal VF examination (1QQQQ).
1.1.3 Evidence
Baseline VF testing is recom-
mended for all patients with an inci-
dentaloma abutting the optic nerves
or chiasm, even without visual symp-
toms (Fig. 1). In one prospective study
of 11 macroincidentalomas, one pa-
tient had VF abnormalities, and two
had compression of the optic chiasm
(8). In other studies, 15% (32) and
5% (4) of patients had unrecognized
VF abnormalities at presentation.
Recommendation
1.1.4 We recommend that all pa-
tients have a MRI scan, if possible, to
evaluate the pituitary incidentaloma (if
the incidentaloma was initially only di-
agnosed by CT scan) to better delineate
the nature and extent of the incidenta-
loma (1QQQQ).
1.1.4 Remarks
For theMRI, a specific pituitary pro-
tocol should be done that includes fine
cuts thorough the sella with and with-
out the administration of the contrast
agent gadolinium. Guidelines for the evaluation of renal
function before administration of gadolinium should be
followed.
2.0 Follow-up testing of the pituitary
incidentaloma
Recommendations
2.1 Patients with incidentalomas who do not meet cri-
teria for surgical removal of the tumor should receive non-
surgical follow-up (2QQEE), with clinical assessments
and the following tests:
2.1.1 MRI scan of the pituitary 6 months after the ini-
tial scan if the incidentaloma is amacroincidentaloma and
1 yr after the initial scan if it is a microincidentaloma
(1QQEE). In patients whose incidentaloma does not
change in size,we suggest repeating theMRI every year for
macroincidentalomas and every 1–2 yr in microinciden-
talomas for the following 3 yr and gradually less fre-
quently thereafter (2QQEE).
2.1.2 VF testing in patients with a pituitary incidenta-
loma that enlarges to abut or compress the optic nerves or
chiasm on a follow-up imaging study (1QQQQ). We sug-
FIG. 1. Flow diagram for the evaluation and treatment of pituitary incidentalomas. a, Baseline
evaluation in all patients should include a history and physical exam evaluating for signs and
symptoms of hyperfunction and hypopituitarism and a laboratory evaluation for hypersecretion. b,
This group may also include large microlesions (see Section 2.1 Evidence). c, The recommendation
for surgery includes the presence of abnormalities of VF or vision and signs of tumor compression
(Section 3.1); surgery is also suggested for other findings (see Section 3.2). d, VF testing is
recommended for patients with lesions abutting or compressing the optic nerves or chiasm at the
initial evaluation and during follow-up. e, Evaluation for hypopituitarism is recommended for the
baseline evaluation and during follow-up evaluations. This is most strongly recommended for
macrolesions and larger microlesions (see Section 1.3). f, Repeat MRI in 1 yr, yearly for 3 yr, and
then less frequently thereafter if no change in lesion size. g, Repeat the MRI in 6 months, yearly
for 3 yr, and then less frequently if no change in lesion size. [Modified from Molitch ME: J Clin
Endocrinol Metab 80:3–6, 1995 (49).]
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gest that clinicians donot need to testVF in patientswhose
incidentalomas are not close to the chiasm and who have
no new symptoms and are being followed closely byMRI
(2QEEE).
2.1.3 Clinical and biochemical evaluations for hypop-
ituitarism 6 months after the initial testing and yearly
thereafter in patients with a pituitary macroincidenta-
loma, although typically hypopituitarism develops with
the finding of an increase in size of the incidentaloma
(1QQEE). We suggest that clinicians do not need to test
for hypopituitarism in patients with pituitary microinci-
dentalomas whose clinical picture, history, and MRI do
not change over time (2QQEE).
2.1 Evidence
Theoptions for treatmentof patientswith asymptomatic,
clinically nonfunctioning pituitary incidentalomas are con-
servative follow-up without surgery (Fig. 1) or immediate
surgery despite the lack of indications for this. Conservative
follow-up was recommended with the recognition that the
proper algorithm for this and its appropriateness and safety
havenotbeen testedprospectively.Fewdataareavailable for
or against anonsurgical approach tomanagementof asymp-
tomatic pituitary incidentalomas. Therefore, evidence in
support of these guidelines also relied on the clinical experi-
ences of the Task Force members.
The proper algorithm for endocrine testing during this
follow-up has not been tested as prospectively conducted
endocrine testing of patients with pituitary incidentalo-
mas who were followed without surgery has only been
reported in 49 patients (8, 9). Follow-up endocrine testing
is recommended for patients with macroincidentalomas
because they are at risk of developing hypopituitarism.Of
the macroincidentalomas followed prospectively, wors-
ening hypopituitarism developed in one of seven (8) and
three of 28 (25) patients, all of whom had enlargement of
their tumors. Hypopituitarism also developed in four of
37 (5) andoneof248 (6) patientswhodevelopedapoplexy
on follow-up. Follow-up endocrine testing was recom-
mendeddespite thepaucityofdatabecauseof thepotential
high risk to the patient of untreated hypopituitarism. In a
meta-analysis of incidentaloma studies, new endocrine
dysfunctiondevelopedoverall in 2.4%ofpatients per year
(3). It is unclear how often new hypopituitarism develops
in the absence of tumor growth. Rapid growth may in-
crease the risk of new hypopituitarism. Routine follow-up
endocrine testing is not required for microincidentalomas
whose clinical picture does not change because the risk of
developing new hypopituitarism is extremely low. In pre-
vious studies, none of the pituitary microincidentalomas
followed prospectively was reported to be associatedwith
changes in pituitary function (4–9).
The proposed algorithms for the MRI follow-up of pi-
tuitary incidentalomas took into account those adopted in
prior studies. However, those algorithms varied consid-
erably from study to study (4–9), and nonewas validated.
As a result, the imaging follow-up proposed in this guide-
line incorporated the experiences of the Task Force’s
members. Follow-up MRI scans were recommended for
macroincidentalomas because it has been demonstrated
that althoughgenerally these lesions growslowly, somedo
enlarge and become symptomatic. In data combined from
a number of studies, macroincidentalomas enlarged in 85
of 353 (24%) patients (4–9, 23–26). VF abnormalities
developed in 28 (8%) patients over time, which demon-
strated that the enlargement adversely affected the pa-
tient’s health. Pituitary apoplexy developed in seven of
353 (2%) patients, of whom most developed permanent
hypopituitarism and one had permanent vision impair-
ment (5). In a meta-analysis of these studies, 8.2% of in-
cidentalomas enlarged per year with a follow-up of 472
person-years (3). Less frequent surveillance of microinci-
dentalomas was recommended because their rate of en-
largement was low, being reported in 17 of 160 patients
(10.6%) followed from 2.3 to 7 yr (5–9, 23–25). In the
meta-analysis, 1.7%ofmicroincidentalomas enlarged per
year (3). Importantly, none of the patients with these mi-
croincidentalomas developed new VF abnormalities that
would have necessitated surgery.
Overall, the Task Force considered that repeat scanning
within the first year was warranted for all patients because,
although most incidentalomas grow slowly, some do en-
large, and the true proliferative nature of the incidentaloma
isunknown(Fig.1). Ifnogrowth isdetected, thenthe interval
betweenMRI scans canbe increased. Evidencedoes not sup-
port one particular algorithm for the frequency of follow-up
imaging, butwe recommendrepeating theMRIeveryyear in
macroincidentalomas, every 1–2 yr in microincidentalomas
for the next 3 yr, and then every other year for the next 6 yr
andgradually less frequently indefinitely so longas the lesion
continues not to threaten the patient’s health. Some Task
Force members would continue imaging every 5 yr. Uncer-
tainty as to the optimal interval and duration of long-term
follow-up imaging can be shared with the patient, and the
scheme followed can be individualized to balance the phy-
sician’s assessment of the risk that the lesion poses to the
patient’s healthwith theburden to thepatient of surveillance
testing.
2.1 Values and preferences
The decision to proceed with conservative nonsurgical
management of pituitary incidentalomas not meeting cri-
teria for surgery (see Section 3.0) puts a relatively high
value on avoiding surgical intervention and its associated
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morbidity and cost, and a relatively low value in avoiding
apoplexy. The evidence that most incidentalomas do not
progress over time to cause visual or other disturbances
supports this value judgment. On the other hand, apo-
plexy developed in seven of 248 patients with incidenta-
lomas (4–6, 8, 9, 26). Large-scale prospective studies of
conservative nonsurgical management of pituitary inci-
dentalomas are needed to further inform this judgment.
2.1 Remarks
The Task Force recognized that a continuum of size of
incidentalomas exists, and some large microincidentalo-
mas (6–9 mm) may behave more like macroincidentalo-
mas. Therefore, some Task Force members would also
perform follow-upMRIs andhypopituitarismevaluations
in larger microincidentalomas as they would for macro-
incidentalomas. Somealso considered that follow-upeval-
uations for hypopituitarismwere needed only for patients
with enlarging incidentalomas because new hypopituitar-
ism would be very unlikely to develop without tumor
growth. However, no data are available to support one
particular size threshold for the increase in size that should
trigger this evaluation. The Task Force was split on these
points.
Recommendation
2.2 Patients who develop any signs or symptoms po-
tentially related to the incidentaloma or who show an in-
crease in size of the incidentalomaonMRI shouldundergo
more frequent or detailed evaluations as indicated clini-
cally (1QQEE).
3.0 Indications for surgical therapy of the pituitary
incidentaloma
Recommendation
3.1 We recommend that patients with a pituitary inci-
dentaloma be referred for surgery if they have the follow-
ing (1QQQQ):
• A VF deficit due to the lesion.
• Other visual abnormalities, such as ophthalmoplegia
or neurological compromise due to compression by
the lesion.
• Lesion abutting or compressing the optic nerves or
chiasm on MRI.
• Pituitary apoplexy with visual disturbance.
• Hypersecreting tumors other than prolactinomas as
recommended by other guidelines of The Endocrine
Society and The Pituitary Society (31, 33).
3.1 Evidence
The decision to recommend surgery as initial therapy for
a patient with a pituitary incidentaloma needs to be individ-
ualized (Fig. 1). Few data are available that specifically ex-
amine the outcome of surgery for incidentalomas. Some of
the evidence considered in developing the recommended cri-
teria for surgery was from transsphenoidal surgical series of
symptomatic and often large pituitary lesions. From these
data and based on the clinical experiences of the Task Force
members, it is clear that substantial evidence supports the
need for surgery for pituitary incidentalomas causing visual
or neurological compromise. The presence of visual or neu-
rological abnormalities due to compression of the optic
nerves or chiasm by the incidentaloma is the strongest indi-
cation for surgery. Although the risks of not performing sur-
gery on tumors that abut the chiasm or for those within cer-
tain proximity of the chiasmbutwhere noVF abnormalities
are present have not been quantified, in the Task Force’s
experience significant risk of future vision disturbance in
thesepatientsexists towarrantsurgery.Theageofthepatient
is also an important consideration. Surgery may be favored
in younger vs. older patients given the higher lifetime prob-
ability of tumor enlargement in the former and the greater
risks of surgical intervention in the latter group of patients.
Some may elect to follow elderly patients with significant
risks to surgery conservatively and closely for any deterio-
ration in vision. The decision to recommend surgery should
also consider whether future fertility is of concern to the pa-
tient. Difficult cases could also be discussed at a pituitary
multidisciplinary team meeting when this is available.
Surgery is indicated in patients with apoplexy and
visual disturbance. In a retrospective review of 30 sub-
jects with pituitary apoplexy, the 20 whowere followed
conservatively had a similar long-term risk of hypopi-
tuitarism as those treated surgically (37). Therefore,
patients with apoplexy and without visual compromise
may be followed conservatively with serial imaging and
hormonal assessments.
3.1 Values and preferences
Ourrecommendations for surgery for incidentalomasput
a high value on alleviating or preventing visual or neurolog-
ical compromise. Although the benefits of surgery in pre-
venting future visual abnormalities are not known, a rela-
tively higher value was put on the prevention of VF
abnormalities than on avoiding the morbidity (e.g. diabetes
insipidus, hypopituitarism) and the cost of surgery.Newhy-
popituitarismas a result of transsphenoidal surgery is rare in
the Task Force’s experience, but the risk should be consid-
ered in the clinical context of the particular patient.
3.1 Remarks
The recommendations for surgical therapy of a pitu-
itary incidentaloma were based on the Task Force’s ex-
pectations for outcome and improvements in vision and
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endocrine function. These expectations were based on
known literature and Task Force members’ clinical expe-
riencewith surgery performedby a surgeon experienced in
transsphenoidal pituitary surgery. The success of surgery
for hormone-secreting tumors is highly dependent on the
expertise, skill, and case volume of a pituitary surgeon
supported by an experienced team (38, 39). This is likely
to also be true for pituitary surgery of other types of le-
sions. The availability of such a pituitary surgeon needs to
be considered when following these guidelines.
Recommendation
3.2 We suggest that surgery be considered for patients
with a pituitary incidentaloma if they have the following
(2QQEE):
• Clinically significant growth of the pituitary
incidentaloma.
• Loss of endocrinological function.




The evidence for or against a recommendation for sur-
gery because of growth of a pituitary incidentaloma is
limited. Surgery was suggested for incidentalomas that
demonstrate clinically significant growth on follow-up
imaging studies, which is growth that could pose a health
risk to the patient such as to their vision. Such growing
incidentalomas typically continue to grow, and surgery is
most effective for smaller lesions. A specific size cutoff for
the incidentaloma was not considered a requirement for
surgery because some large incidentalomas are predomi-
nantly intra- and infrasellar. Although there are no estab-
lished changes in size or growth rate that would automat-
ically trigger the need for surgery, the pattern of growth of
the incidentaloma was considered more important. For
example, a 1-mm enlargement within the sella of a 5-mm
intrasellar microadenoma would not be clinically signifi-
cant, but a 1-mm enlargement toward the chiasm in a
lesion only 3 mm from the chiasm would be significant.
Therefore, incidentalomas exhibiting significant growth
(which includes growth that is rapid, occurring over a 1-
to 2-yr period, and/or that is toward the optic chiasm and
if continued could threaten vision in the near future)
should be considered for surgery before the incidentaloma
progresses to abut the chiasm or produce visual deficits. A
consideration of the clinical characteristics of the patient
including their age and other risks for surgery needs to be
incorporated into the decision to proceed to surgery.
The evidence for or against a recommendation for sur-
gery because of the presence of hypopituitarism is also
limited. Although some surgical series of symptomatic in-
cidentalomas show that hypopituitarism can improve
with surgery (40, 41), these data may not be applicable to
the incidentaloma, and as a result hypopituitarism was
consideredonlya relative indication for surgery.Adequate
replacement therapy should be instituted whether or not
surgery is recommended. Some patients planning preg-
nancy may benefit from surgery if their tumor is close to
the optic chiasm because there is a small risk that lac-
totrophhyperplasia in thenormal glandmay lead to tumor
compression of the optic nerve or chiasm, and closer fol-
low-up in such patients should be undertaken. Headache
may ormay not improve with transsphenoidal removal of
the tumor, so it can only be suggested as an indication for
surgery, and the quality of evidence is low.
Medical therapy of the pituitary incidentaloma
In patients with incidentalomas and hyperprolactine-
mia that may be due to tumoral compression of the hy-
pothalamic-pituitary stalk, symptomatichyperprolactine-
mia may be treated with a dopamine agonist. However,
incidentalomas other than a prolactinoma will rarely
shrink, and dopamine agonists cannot be relied upon for
this purpose. Therefore, continued monitoring of lesion
size is necessary, regardless of changes in prolactin levels.
Medical therapy of pituitary incidentalomas has not
been systematically studied. Someparallels to the effects of
medical therapy on pathologically confirmed nonfunc-
tioning pituitary tumors are possible, but this connection
needs to be made cautiously. The reported efficacy of do-
pamine agonist therapy of nonfunctioning pituitary ade-
nomas varies widely. With cabergoline or bromocriptine
treatment for patients with residual tumor after surgery,
some degree of tumor shrinkage was detected in 8–45%
(42–44), and the amount of shrinkage varied from 10–
62%(43,44)or3–14mm(42). Somatostatinanalogshave
also been tried.With nomore than 1 yr of octreotide ther-
apy, shrinkage was reported in approximately 5–25%,
increase in 12%, and stabilization in 83% of tumors (45–
48). Insufficient data are available to suggest the routine
use of medical therapy of pituitary incidentalomas.
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